Phase 3 Recruiting Industry
The purpose of this study is to compare the efficacy of Nivolumab and Relatlimab in combination with chemotherapy to Pembrolizumab with Chemotherapy in participants with stage IV or recurrent Non-squamous Non-small Cell Lung Cancer with PD…
Sponsor: Bristol-Myers Squibb
NCT ID: NCT06561386
Sites in Alabama: - Local Institution - 0487 — Mobile, Alabama
Phase 2, Phase 3 Recruiting Industry
This is a Phase 2/3, multisite, randomized, open-label study in participants with first-line non-small cell lung cancer (NSCLC). This study includes two substudies (substudy A and substudy B) that will recruit participants according to his…
Sponsor: BioNTech SE
NCT ID: NCT06712316
Sites in Alabama: - Birmingham Hematology and Oncology Associates LLC d/b/a Alabama Oncology — Birmingham, Alabama
Phase 2 Recruiting Industry
The purpose of this study is to determine if treatment with a single dose of RE104 for Injection reduces depressive symptoms or depressive symptoms mixed with anxiety symptoms in participants with Adjustment Disorder due to cancer or other…
Sponsor: Reunion Neuroscience Inc
NCT ID: NCT07002034
Sites in Alabama: - UAB, Psychiatry and Behavioral Neurology — Birmingham, Alabama
Phase 2 Recruiting Industry
PUMA-ALI-4201 is a Phase 2 study evaluating alisertib monotherapy in patients with pathologically-confirmed small cell lung cancer (SCLC) following progression on or after treatment with one platinum-based chemotherapy and anti-PD-L1/PD-1 …
Sponsor: Puma Biotechnology, Inc.
NCT ID: NCT06095505
Sites in Alabama: - Southern Cancer Center — Daphne, Alabama
Phase 1, Phase 2 Recruiting Industry
This study is designed to evaluate the safety and efficacy of ifinatamab deruxtecan (I-DXd) in combination with immune checkpoint inhibitor (ICI) atezolizumab with or without carboplatin in participants with extensive stage-small cell lung…
Sponsor: Daiichi Sankyo
NCT ID: NCT06362252
Sites in Alabama: - University of Alabama -Birmingham — Birmingham, Alabama
Phase 2 Recruiting Industry
The purpose of this study is to evaluate the safety, efficacy and pharmacokinetics (PK) of zipalertinib in participants with locally advanced or metastatic Non-Small Cell Lung Cancer (NSCLC) harboring EGFR ex20ins mutations and other mutat…
Sponsor: Taiho Oncology, Inc.
NCT ID: NCT05967689
Sites in Alabama: - University of Alabama at Birmingham — Birmingham, Alabama
Phase 1, Phase 2 Recruiting Industry
The study treatment, BAY 3713372, is under development to treat MTAP (methylthioadenosine phosphorylase)-deleted solid tumors. It is thought to work by blocking the protein arginine N-methyltransferase 5 (PRMT5). This may kill the MTAP-del…
Sponsor: Bayer
NCT ID: NCT06914128
Sites in Alabama: - UAB O'Neal Comprehensive Cancer Center - The Kirklin Clinic of UAB Hospital — Birmingham, Alabama
Phase 2 Recruiting Industry
The main goals are after treatment given before surgery, to measure the number of people who have no signs of cancer cells in tumors and lymph nodes removed during surgery; and to learn about whether the cancer gets smaller or goes away by…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06788912
Sites in Alabama: - Southern Cancer Center (SCC) ( Site 8004) — Daphne, Alabama
Phase 2 Recruiting Industry
This is an exploratory, signal finding, randomized, placebo-controlled, blinded, multi-center Phase 2b trial of the anti GDF-15 antibody Visugromab (CTL-002) versus Placebo, combined with Immunochemotherapy (ICT: Pembrolizumab, Pemetrexed,…
Sponsor: CatalYm GmbH
NCT ID: NCT07098988
Sites in Alabama: - University of Alabama at Birmingham — Birmingham, Alabama
Phase 2 Recruiting Industry
This is an exploratory, signal-finding, randomized, placebo-controlled, blinded, multi-center phase 2b trial of the anti-GDF-15 antibody Visugromab (CTL-002) at two different dose levels plus Nivolumab with Docetaxel versus Visugromab at t…
Sponsor: CatalYm GmbH
NCT ID: NCT07246863
Sites in Alabama: - University of Alabama at Birmingham (O'Neal Comprehensive Cancer Center) — Birmingham, Alabama
Phase 1, Phase 2 Recruiting Industry
A Phase 1/2a Dose Escalation and Expansion Study of the Safety, Tolerability, and Preliminary Clinical Activity of 177LuBetaBart, a 177Lu-Labeled Anti-B7-H3 Monoclonal Antibody, in Patients with Relapsed/Refractory, Locally Advanced Inoper…
Sponsor: Radiopharm Theranostics, Ltd
NCT ID: NCT07189871
Sites in Alabama: - Dothan Hematology & Oncology — Dothan, Alabama
Phase 1 Recruiting Industry
The purpose of this study is to evaluate the safety, tolerability, dosimetry and preliminary efficacy of \[177Lu\]Lu-NNS309 and the safety, dosimetry and imaging properties of \[68Ga\]Ga-NNS309 in patients aged ≥ 18 years with locally adva…
Sponsor: Novartis Pharmaceuticals
NCT ID: NCT06562192
Sites in Alabama: - Uni of Alabama at Birmingham — Birmingham, Alabama
Recruiting Academic/Other
The goal of the study is to collect data on patients treated outside of a clinical trial (in routine clinical practice) with standard of care osimertinib with or without chemotherapy in Epidermal Growth Factor Receptor (EGFR)-mutant Non-Sm…
Sponsor: PrECOG, LLC.
NCT ID: NCT06538038
Sites in Alabama: - University of Alabama at Birmingham — Birmingham, Alabama
Recruiting Industry
This longitudinal study looks to quantify the testing timeline, operational barriers, and outcomes of biomarker-guided therapy in a large, community-based, and largely unselected patient population with early stage and advanced stage, trea…
Sponsor: US Oncology Research
NCT ID: NCT05885698
Sites in Alabama: - Southern Cancer Center, PC — Daphne, Alabama